Nov 27, 2018
Regulatory approval of CAR-T cell therapies in 2017 placed the spotlight on immunotherapy approaches that use live cells to attack tumours – a major shift in oncology treatment.
Yet even this groundbreaking therapy has limitations, such as when patients already immuno-depressed from a first-line treatment do not have sufficient T-cells to modify or stimulate.
For this reason, investigators are looking to natural killer cell therapy (NK cell therapy) as the next frontier of immunotherapy for the fight against cancer.
As the evolution of precision medicine continues, NK cell therapy will play an important role in guiding efficacious treatments.
Original article by Dr Azusa Tanaka and Dr Michael Seiler of Taconic Biosciences
If you'd like to view the original article then follow the link below:
You can also download the original article pdf here:
For more information on Drug Discovery World, head to: